SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

Read more breaking news

 

 
News in brief

UAE Allows Patented API Imports to Reduce Local Generic Delay

22-Jul-2013
Last updated on 22-Jul-2013 at 13:05 GMT

The UAE says it will allow generic drug manufacturers to import active ingredients of patented drugs to encourage local industry growth.

Following a meeting last week between the UAE Ministry of Health (MoH) and local pharma manufacturers, Dr. Amin Al Amiri - Assistant Undersecretary for Medical Practices and Licensing in the UAE – announced factories will be allowed to import active substances for the purposes of research, development and bioequivalence studies before the patent has expired.

Al Amiri told the Gulf News this will benefit both the consumer and the UAE’s pharma industry. “Generic market entry is often delayed because a manufacturer has to invest up to 18-24 months for clinical study and research before marketing the generic drug.”

Such a move will allow generic versions of drugs to be immediately available once patent has expired from the 15 companies at the meeting who currently make the 940 drugs produced locally. 

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions